Drug manufacturers must now prioritize glycosylation control in the development of complex biologics, including bispecific antibodies, antibody-drug conjugates, and Fc-fusion proteins. These newer therapeutics are sensitive to glycan heterogeneity, which can directly affect their efficacy and consistency.
Historically, manufacturers addressed glycosylation issues during downstream processing. However, modern biologics require proactive upstream quality engineering to mitigate risks associated with glycosylation variability. This shift is essential to meet regulatory expectations and improve process consistency throughout development.
Integrating glycosylation considerations early in the development process can prevent batch rejections and regulatory delays. Additionally, clone selection is critical, as around 80% of glycosylation variability stems from the production clone’s intrinsic characteristics. Advanced analytical technologies are increasingly used to assess glycosylation-related attributes during early-stage development.
As biologic systems grow more complex, structured methodologies and automated systems will be vital for managing glycosylation control effectively. Companies that adapt to these changes will be better positioned to ensure consistent therapeutic performance and meet evolving regulatory demands.
Source: genengnews.com · Image: "Dr. Kilmer's Standard Herbal Remedies" Residence, consulting rooms, dispensary, and laboratory, Binghamton, N. Y. A trial by jury. Use Dr. Kilmer's Prompt Parilla Liver Pills. (front) by Boston Public Library, CC BY 2.0, via Wikimedia Commons
Start your 7-day trial and see what the database can do →
